跳至主要内容
临床试验/JPRN-UMIN000023217
JPRN-UMIN000023217已完成2 期

A phase II trial of conversion surgery after induction chemotherapy(Gemcitabine+nab-Paclitaxel) and chemoradiotherapy(RT+S-1) for the patients with locally advanced pancreatic cancer. - GENPARTS-CS trial

Ochanomizu Gastrointestinal Oncology Group0 个研究点目标入组 11 人开始时间: 2016年9月1日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
11

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 80years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1)-1 Initially diagnosed as resectable pancreatic cancer -2 Initially diagnosed as unresectable pancreatic cancer with distant metastasis 2)Age: over 80 years, or less than 20 years 3)ECOG performance status =>2 4)Previous treatments 5)Labodata do not satisfy inclusion criteria 6)No written informed consent 7)Inadequate physical condition, as diagnosed by primary physician

研究者

发起方
Ochanomizu Gastrointestinal Oncology Group

相似试验